Literature DB >> 15685592

Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms.

Joaquim Carreras1, Neus Villamor, Lluís Colomo, Carol Moreno, Santiago Ramón y Cajal, Marta Crespo, Frederic Tort, Francesc Bosch, Armando López-Guillermo, Dolors Colomer, Emili Montserrat, Elías Campo.   

Abstract

ZAP-70 is a tyrosine kinase that participates in early B-cell differentiation and is a prognostic factor in chronic lymphocytic leukaemia (CLL), where it is associated with an unmutated configuration of the IgV(H) genes. In this study ZAP-70 expression was studied by immunohistochemistry in a spectrum of B-cell lymphoid neoplasms; this staining method was compared with flow cytometry, and the relationship of ZAP-70 expression to mutational status and prognosis was assessed. 242 tissue samples from 225 patients with B-cell lymphoid neoplasms arising at different maturational stages were included. Flow cytometry was performed in all CLL cases (n = 52). IgV(H) mutational status was determined in 25 CLL and 12 mantle cell lymphoma (MCL) patients. ZAP-70 was positive in 34/52 (65%) CLL, 9/31 (31%) Burkitt's lymphoma, 2/7 (29%) lymphoblastic lymphomas, 3/36 (8%) MCL, 1/23 (4%) marginal zone lymphoma, and 1/45 (2%) diffuse large B-cell lymphomas, but in none of the 19 follicular lymphomas or the 14 Hodgkin lymphomas. An identical ZAP-70 pattern was obtained in six patients with simultaneous biopsies from different sites and in 12 patients with sequential biopsies. Immunohistochemistry and flow cytometry gave identical results in 48 the 52 CLLs. All but one ZAP-70-positive CLL had IgV(H) gene in an unmutated configuration, whereas all but one ZAP-70-negative CLL had somatically hypermutated IgV(H). The 12 MCLs analysed were ZAP-70 negative regardless of IgV(H) mutational status (4 mutated, 8 unmutated). ZAP-70 positive CLL was associated with a shorter overall survival (median time 103 months vs. 293 months, p = 0.01) and a shorter time to disease progression (median time 26 months vs. 60 months, p = 0.01). In conclusion, ZAP-70 is expressed in several types of B-cell neoplasm and is easily detected by immunohistochemistry, providing a useful prognostic marker in patients with CLL from whom no other material is available or when other techniques for its assessment cannot be performed.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15685592     DOI: 10.1002/path.1727

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  17 in total

1.  Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior.

Authors:  Eva Giné; Antoni Martinez; Neus Villamor; Armando López-Guillermo; Mireia Camos; Daniel Martinez; Jordi Esteve; Xavier Calvo; Ana Muntañola; Pau Abrisqueta; Maria Rozman; Ciril Rozman; Francesc Bosch; Elias Campo; Emili Montserrat
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

2.  Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Sonia Jain; Michael J Keating; William G Wierda; Michael R Grever; John C Byrd; Neil E Kay; Jennifer R Brown; John G Gribben; Donna S Neuberg; Feng He; Andrew W Greaves; Kanti R Rai; Thomas J Kipps
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

Review 3.  How I treat CLL up front.

Authors:  John G Gribben
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

4.  Differential and tumor-specific expression of CD160 in B-cell malignancies.

Authors:  Timothy W Farren; Jerome Giustiniani; Feng-Ting Liu; Dimitris A Tsitsikas; Marion G Macey; James D Cavenagh; Heather E Oakervee; David Taussig; Adrian C Newland; Maria Calaminici; Armand Bensussan; Michael Jenner; John G Gribben; Samir G Agrawal
Journal:  Blood       Date:  2011-06-28       Impact factor: 22.113

5.  B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.

Authors:  Elena Sabattini; Rocio Orduz; Cristina Campidelli; Pier Luigi Zinzani; Vincenzo Callea; Simona Zupo; Giovanna Cutrona; Fortunato Morabito; Manlio Ferrarini; Stefano Pileri
Journal:  J Clin Pathol       Date:  2006-08-17       Impact factor: 3.411

Review 6.  Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia.

Authors:  Tom Butler; J G Gribben
Journal:  Blood Rev       Date:  2010-04-15       Impact factor: 8.250

Review 7.  Newer developments in immunohistology.

Authors:  A S-Y Leong; T Y-M Leong
Journal:  J Clin Pathol       Date:  2006-11       Impact factor: 3.411

8.  Immunohistochemical detection of ZAP70 in chronic lymphocytic leukemia predicts immunoglobulin heavy chain gene mutation status and time to progression.

Authors:  Joan H Admirand; Ronald J Knoblock; Kevin R Coombes; Constantine Tam; Ellen J Schlette; William G Wierda; Alessandra Ferrajoli; Susan O'Brien; Michael J Keating; Rajyalakshmi Luthra; L Jeffrey Medeiros; Lynne V Abruzzo
Journal:  Mod Pathol       Date:  2010-07-23       Impact factor: 7.842

9.  Hodgkin lymphoma variant of Richter transformation: morphology, Epstein-Barr virus status, clonality, and survival analysis-with comparison to Hodgkin-like lesion.

Authors:  Wenbin Xiao; Wayne W Chen; Lynn Sorbara; Theresa Davies-Hill; Stefania Pittaluga; Mark Raffeld; Elaine S Jaffe
Journal:  Hum Pathol       Date:  2016-05-14       Impact factor: 3.466

10.  Quantitative detection of zeta-chain-associated protein 70 expression in chronic lymphocytic leukemia.

Authors:  Peixuan Zhu; Heba A Degheidy; Gerald E Marti; Shuhong Li; Fatima Abbasi; Adrian Wiestner; Platte Amstutz; Cha-Mei Tang
Journal:  Leuk Lymphoma       Date:  2012-08-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.